Your browser doesn't support javascript.
loading
Textbook Oncological Outcome in European GASTRODATA.
Sedlak, Katarzyna; Rawicz-Pruszynski, Karol; Mlak, Radoslaw; Van Sandick, Johanna; Gisbertz, Suzanne; Pera, Manuel; Dal Cero, Mariagiulia; Baiocchi, Gian Luca; Celotti, Andrea; Morgagni, Paolo; Vittimberga, Giovani; Hoelscher, Arnulf; Moenig, Stefan; Kolodziejczyk, Piotr; Richter, Piotr; Gockel, Ines; Piessen, Guillaume; Da Costa, Paulo Matos; Davies, Andrew; Baker, Cara; Allum, William; Romario, Uberto Fumagalli; De Pascale, Stefano; Rosati, Ricccardo; Reim, Daniel; Santos, Lucio Lara; D'ugo, Domenico; Wijnhoven, Bas; Degiuli, Maurizio; De Manzoni, Giovanni; Kielan, Wojciech; Frejlich, Ewelina; Schneider, Paul; Polkowski, Wojciech P.
Afiliação
  • Sedlak K; Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
  • Rawicz-Pruszynski K; Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
  • Mlak R; Department of Preclinical Sciences, Body Composition Research Laboratory, Medical University of Lublin, Lublin, Poland.
  • Van Sandick J; Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Gisbertz S; Department of Surgery, University Medical Center, Amsterdam, The Netherlands.
  • Pera M; Department of Digestive Surgery, Hospital Universitario del Mar, Barcelona, Spain.
  • Dal Cero M; Department of Digestive Surgery, Hospital Universitario del Mar, Barcelona, Spain.
  • Baiocchi GL; Department of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, and Third Division of General Surgery, Spedali Civili di Brescia, Brescia, Italy.
  • Celotti A; Department of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, and Third Division of General Surgery, Spedali Civili di Brescia, Brescia, Italy.
  • Morgagni P; Department of General Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
  • Vittimberga G; Department of General Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy.
  • Hoelscher A; Agaplesion Markus Krankenhaus, Frankfurt, Germany.
  • Moenig S; Department of General, Visceral and Thoracic Surgery, Agaplesion Markus Hospital, Frankfurt, Germany.
  • Kolodziejczyk P; Department of Surgery, Jagiellonian University Medical College.
  • Richter P; Department of Surgery, Jagiellonian University Medical College.
  • Gockel I; Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany.
  • Piessen G; Department of Digestive and Oncological Surgery, University Lille, and Claude Huriez University Hospital, Lille, France.
  • Da Costa PM; General Surgery Department, Hospital Garcia de Orta, Lisbon, Portugal.
  • Davies A; Department of Upper Gastrointestinal and General Surgery, Guy's and St Thomas' Hospital, London, UK; School of Cancer and Pharmaceutical Sciences, King's College; Department of Molecular Medicine and Surgery and Upper Gastrointestinal Surgery, Karolinska Institute, Stockholm, Sweden, London, UK.
  • Baker C; Department of Upper Gastrointestinal and General Surgery, Guy's and St Thomas' Hospital, London, UK; School of Cancer and Pharmaceutical Sciences, King's College; Department of Molecular Medicine and Surgery and Upper Gastrointestinal Surgery, Karolinska Institute, Stockholm, Sweden, London, UK.
  • Allum W; Department of Surgery, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Romario UF; Digestive Surgery, European Institute of Oncology, IRCCS, Milan, Italy.
  • De Pascale S; Digestive Surgery, European Institute of Oncology, IRCCS, Milan, Italy.
  • Rosati R; Department of Gastrointestinal Surgery, San Raffaele Hospital, Milan, Italy.
  • Reim D; Department of Surgery, TUM School of Medicine, Technical University of Munich, Germany.
  • Santos LL; Department of Surgical Oncology, Experimental Pathology and Therapeutics Group, Portuguese Institute Of Oncology, Porto, Portugal.
  • D'ugo D; Department of General Surgery, Fondazione Policlinico Gemelli, Rome, Italy.
  • Wijnhoven B; Department of General Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Degiuli M; Surgical Oncology and Digestive Surgery, Department of Oncology, University of Turin, San Luigi University Hospital, Orbassano, Turin 10049, Italy.
  • De Manzoni G; Department of Surgery, General and Upper G.I. Surgery Division, University of Verona, Verona, Italy.
  • Kielan W; Department of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland.
  • Frejlich E; Department of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland.
  • Schneider P; Department of Infectious Diseases and Pulmonary Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
  • Polkowski WP; Department of Surgical Oncology, Medical University of Lublin, Lublin, Poland.
Ann Surg ; 278(5): 823-831, 2023 11 01.
Article em En | MEDLINE | ID: mdl-37555342
OBJECTIVE: To assess the rate of textbook outcome (TO) and textbook oncological outcome (TOO) in the European population based on the GASTRODATA registry. BACKGROUND: TO is a composite parameter assessing surgical quality and strongly correlates with improved overall survival. Following the standard of treatment for locally advanced gastric cancer, TOO was proposed as a quality and optimal multimodal treatment parameter. METHODS: TO was achieved when all the following criteria were met: no intraoperative complications, radical resection according to the surgeon, pR0 resection, retrieval of at least 15 lymph nodes, no severe postoperative complications, no reintervention, no admission to the intensive care unit, no prolonged length of stay, no postoperative mortality and no hospital readmission. TOO was defined as TO with the addition of perioperative chemotherapy compliance. RESULTS: Of the 2558 patients, 1700 were included in the analysis. TO was achieved in 1164 (68.5%) patients. The use of neoadjuvant chemotherapy [odds ratio (OR) = 1.33, 95% CI: 1.04-1.70] and D2 or D2+ lymphadenectomy (OR = 1.55, 95% CI: 1.15-2.10) had a positive impact on TO achievement. Older age (OR = 0.73, 95% CI: 0.54-0.94), pT3/4 (OR = 0.79, 95% CI: 0.63-0.99), ASA 3/4 (OR = 0.68, 95% CI: 0.54-0.86) and total gastrectomy (OR = 0.56, 95% CI: 0.45-0.70), had a negative impact on TO achievement. TOO was achieved in 388 (22.8%) patients. Older age (OR = 0.37, 95% CI: 0.27-0.53), pT3 or pT4 (OR = 0.52, 95% CI: 0.39-0.69), and ASA 3 or 4 (OR = 0.58, 95% CI: 0.43-0.79) had a negative impact on TOO achievement. CONCLUSIONS: Despite successively improved surgical outcomes, stage-appropriate chemotherapy in adherence to the current guidelines for multimodal treatment of gastric cancer remains poor. Further implementation of oncologic quality metrics should include greater emphasis on perioperative chemotherapy and adequate lymphadenectomy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas Tipo de estudo: Etiology_studies / Guideline / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas Tipo de estudo: Etiology_studies / Guideline / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article